Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IGEN International -- Ignore unavailable to you. Want to Upgrade?

To: James Perry who wrote (396)	7/31/1998 1:58:00 AM
From: John Zwiener	Read Replies (2) \| Respond to of 1025

James , your right , it's major. I don't know what the stock will do short term, but the writing is being writen on the walls, like sepracor is, but Igen is better, IMO. I feel strongly that Igen is exceeding my expectations. I understand it is very difficult is see what is going on. From the trading going on, I think someone is still shorting the stock, but right after that someone picks up the drop in price and buys those shares. We might see a very nice squeeze eventually, and I don't usually speculate on a short term thing like that,,,and it is not important since any short squeeze would not be important in the long term. I'm back to the point of where Igen was 5 and I thought is was worth 30. This is a company where vision is important. Igen should be over 100 based on today's idea of what biotechs go for. It may take 2 or 3 quarters for realization of the probable upcoming revenues could be, but eventually it will be seen by those following this company and waiting for whatever they need to see is there. When things come together, we are looking at very substantial revenues coming in from many directions. So at this point, we have an undervalued company again, on a massive scale, in my opinion. Yes, if a POC agreement comes through, it is probably going to cause a major move. I believe that Walstadler was hinting that Abbott might be the company that would raise eyebrows as wanting to make a deal with Igen. It's the only company that would do that for me. I think this is a clear message for Roche. I think Walstadler is underestimating the royalties coming to Igen on purpose ,,,for the larger picture of good relationships. He is willing to let Roche get away with a little underpayment because of their committment to electsys, but he made it clear that this is it. Come clean, or they will go with someone else. I wouldn't be surprise to see them revoke Roche's license and sell it to Abbott if Abbott made up for all revenue coming to Igen. And Abbott would do it because it would destroy Roche as a competator, and Igen would still come out on top. My opinion is this is Roche's big chance to catch and beat Abbott in the central lab area. If Abbott takes it, Roche is out of the laboratory business. This is that big IMO. Roche has to stop playing BMG's game, probably need to fire the old BMG idiots who have put Roche in this losing game. They aren't big enough to lead Roche against Abbott. So we are at a decision point. Will Roche continue to play games? It would be a mistake IMO. I have never heard Wolstadler sound as solid and determined and positive as this evening. The chief guy played down the idea that a big deal may be about to come,,,but I think there is about to be deals, major, about to be announced. He sounded like he did when Igen was 5. Yes, traders could move it down, but that's biotech. The current Roche deal is small compared to the potential. The question is will Roche participate in the big POC move. Will they dominate it? I'll bet that Roche will miss it, POC (though they will probably do enough to keep their deal with Igen). HP will take it and beat everyone by a year to POC. they will totally dominate the newest, most profitable part of testing in 2 decades. Maybe someone smart in Roche will read this, but they won't be able to do anything about it because their corporation is European and socialistic, and HP is becoming primed to take advantage of this opportunity. the wild card is Abbott. I'll bet that HP in the end is the one that can carry the ball. Abbott is too confident, even if they get the deal. (How do you like this speculation James). Igen owns the best measuring technology in 2 decades, and I don't see another one like it on the horizon. And they have kept control of it. This is like xerox or polaroid at the beginning, and it could move like Amgen. I don't love this stock, but I'm continuously surprised at how much better the news is than I've expected, and I like what I see. There is a beauty in the technology and management's ability to execute it. Summary, Igen is still best pick in biotech. SEPR is best for amatuer in biotech because it's easier to understand, but Igen has better legs.